

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

60 2537

APPLICATION FOR A STANDARD PATENT

American Cyanamid Company, of One Cyanamid Plaza, Wayne, New Jersey, UNITED STATES OF AMERICA, hereby apply for the grant of a standard patent for an invention entitled:

Acylation Products of Bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde

which is described in the accompanying complete specification.

APPLICATION ACCEPTED AND AMENDMENTS

Details of basic application(s):-

ALLOWED 3-8-90

Basic Applic. No: Country:

Application Date:


922220

UNITED STATES OF AMERICA

23 October 1986

The address for service is:-

Spruson & Ferguson
Patent Attorneys
Level 33 St Martins Tower
31 Market Street
Sydney New South Wales Australia



DATED this TWENTY SECOND day of OCTOBER 1987


American Cyanamid Company

By:

Registered Patent Attorney

TO: THE COMMISSIONER OF PATENTS
OUR REF: 41308
S&F CODE: 50380

5845/2



DECLARATION IN SUPPORT OF A
CONVENTION APPLICATION FOR A PATENT

In support of the Convention Application made for a
patent for an invention entitled: ACYLATION PRODUCTS OF BIS(2-
IMIDAZOLIN-2-YLHYDRAZONES) OF 9,10-ANTHRACENEDICARBOXALDEHYDE

Title of Invention

I/We JOHN J. HAGAN,

Full name(s) and
address(es) of
Declarant(s)

of 86 Ocean Drive East, Stamford, State of Connecticut,
United States of America,

do solemnly and sincerely declare as follows:-

Full name(s) of
Applicant(s)

1. ~~I am/We are the applicant(s) for the patent~~

(or, in the case of an application by a body corporate)

1. I am/We are authorised by

AMERICAN CYANAMID COMPANY
the applicant(s) for the patent to make this declaration on
its/their behalf.

2. The basic application(s) as defined by Section 141 of the
Act was/were made

Basic Country(ies)

in United States of America

Priority Date(s)

on October 23, 1986

Basic Applicant(s)

by KEITH CHADWICK MURDOCK

Full name(s) and
address(es) of
inventor(s)

3. ~~I am/We are the actual inventor(s) of the invention referred
to in the basic application(s)~~

(or where a person other than the inventor is the applicant)

3. KEITH CHADWICK MURDOCK, a citizen of the United
States of America,

of 15 Birch Street, Pearl River, New York 10965,
United States of America

-(respectively)-

is/are the actual inventor(s) of the invention and the facts upon
which the applicant(s) is/are entitled to make the application are
as follows: 1 Assignment dated 28th October 1986
assigning said invention from said inventore
to the said company.

Set out how Applicant(s)
derive title from actual
inventor(s) e.g. The
Applicant(s) is/are the
assignee(s) of the
invention from the
inventor(s)

4. The basic application(s) referred to in paragraph 2 of this
Declaration was/were the first application(s) made in a Convention
country in respect of the invention(s) the subject of the application.

Declared at Stamford, this 4th day of Dec. 1987
Connecticut, U.S.A.

AMERICAN CYANAMID COMPANY
BY:


John J. Hagan
John J. Hagan, Manager
Patent Law Department

To: The Commissioner of Patents

11/81

(12) PATENT ABRIDGMENT (11) Document No. AU-B-80033/87
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 602537

- (54) Title
ACYLATION PRODUCTS OF BIS(2-IMIDAZOLIN-2-YLHYDRAZONES) OF
9,10-ANTHRACENEDICARBOXALDEHYDE
- International Patent Classification(s)
(51)⁴ C07D 233/52 C07D 405/14 C07F 009/65 A61K 031/415
- (21) Application No. : 80033/87 (22) Application Date : 22.10.87
- (30) Priority Data
- (31) Number (32) Date (33) Country
922220 23.10.86 US UNITED STATES OF AMERICA
- (43) Publication Date : 28.04.88
- (44) Publication Date of Accepted Application : 18.10.90
- (71) Applicant(s)
AMERICAN CYANAMID COMPANY
- (72) Inventor(s)
KEITH CHADWICK MURDOCK
- (74) Attorney or Agent
SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001
- (57) Specifically this invention is concerned with
compounds of the formula:




wherein R_1 and R_3 are the same or different and are:
hydrogen, alkyl(C_1-C_6),

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{R}_5 \end{array}$ (where R_5 is hydrogen, alkyl(C_1-C_6), phenyl, mono-substituted phenyl (wherein the substituent may be

(11) AU-B-80033/87
(10) 602537

-2-

ortho, meta or para and is fluoro, nitro, alkyl(C₁-C₆), alkoxy(C₁-C₃) or cyano), pentafluorophenyl, naphthyl, furanyl,



$-\text{SO}_3\text{H}$; R₂ and R₄ are the same or different and are: hydrogen, alkyl(C₁-C₄)

or

$-\text{C}(=\text{O})\text{R}_6$ ((where R₆ is hydrogen, alkyl(C₁-C₆), phenyl, monosubstituted phenyl (wherein the substituent may be in the ortho, meta or para position and is fluoro, nitro, alkyl(C₁-C₆), alkoxy(C₁-C₃) or cyano), pentafluorophenyl, naphthyl, furanyl or $-\text{CH}_2\text{OCH}_3$); together with the pharmacologically acceptable salts thereof. Generally only one of R₁ and R₃ may be hydrogen or alkyl(C₁-C₆).

Special mention is made of the monophosphoramidic acids embraced by the foregoing formula. Their anti-tumor activity is coupled with a lack of painful phlebitis near the site of injection when administered to some warm-blooded animals.

S & F Ref: 41308

FORM 10

COMMONWEALTH OF AUSTRALIA

PATENTS ACT 1952

COMPLETE SPECIFICATION

(ORIGINAL)

FOR OFFICE USE:

Class Int Class

60 25 37

Complete Specification Lodged:
Accepted:
Published:

Priority:

Related Art:

SEARCHED	SERIALIZED
INDEXED	FILED

Name and Address
of Applicant:

American Cyanamid Company
One Cyanamid Plaza
Wayne New Jersey
UNITED STATES OF AMERICA

Address for Service:

Spruson & Ferguson, Patent Attorneys
Level 33 St Martins Tower, 31 Market Street
Sydney, New South Wales, 2000, Australia

Complete Specification for the invention entitled:

Acylation Products of Bis(2-imidazolin-2-ylhydrazones) of
9,10-anthracenedicarboxaldehyde

The following statement is a full description of this invention, including the
best method of performing it known to me/us

30,487

TITLE: ACYLATION PRODUCTS OF
BIS(2-IMIDAZOLIN-2-
YLHYDRAZONES) OF 9,10-
ANTHRACENEDICARBOXALDEHYDE

ABSTRACT OF DISCLOSURE

N-acylated derivatives of bis(2-imidazolin-2-ylhydrazoles) of 9,10-anthracenedicarboxaldehyde, useful as anti-cancer agents, are disclosed and described, including processes for manufacture and use.

Title: ACYLATION PRODUCTS OF BIS (2-
IMIDAZOLIN-2-YLHYDRAZONES) OF
9,10-ANTHRACENEDICARBOXALDEHYDE

5


This invention is concerned with new organic compounds which are N-acylated derivatives of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde.

10

The unacylated precursor compounds are disclosed in U.S. Patent 4,258,181.

15

Specifically this invention is concerned with compounds of the formula:




wherein R₁ and R₃ are the same or different and are:
hydrogen, alkyl(C₁-C₆),

$\text{-}\overset{\text{O}}{\parallel}\text{C-R}_5$ (where R₅ is hydrogen, alkyl(C₁-C₆), phenyl, mono-substituted phenyl (wherein the substituent may be

20

ortho, meta or para and is fluoro, nitro, alkyl(C₁-C₆), alkoxy(C₁-C₃) or cyano), pentafluorophenyl, naphthyl, furanyl,



-SO₃H; R₂ and R₄ are the same or different and are: hydrogen, alkyl(C₁-C₄)

or


$-\text{C}-\text{R}_6$ (where R₆ is hydrogen, alkyl(C₁-C₆), phenyl, monosubstituted phenyl (wherein the substituent may be in the ortho, meta or para position and is fluoro, nitro, alkyl(C₁-C₆), alkoxy(C₁-C₃) or cyano), pentafluorophenyl, naphthyl, furanyl or -CH₂OCH₃); together with the pharmacologically acceptable salts thereof. Generally only one of R₁ and R₃ may be hydrogen or alkyl(C₁-C₆).

Special mention is made of the monophosphoramidic acids embraced by the foregoing formula. Their anti-tumor activity is coupled with a lack of painful phlebitis near the site of injection when administered to some warm-blooded animals.


The compounds of the present invention are obtainable as yellow to orange crystalline materials having characteristic melting points and adsorption spectra, and which may be purified by recrystallization from common organic solvents such as lower alkanols, dimethylformamide, methyl isobutyl ketone and the like.



The compounds of the present invention may be readily prepared in accordance with the following reaction scheme:



Scheme (continued)



(1)

where A is an acylating agent (2) including carboxylic acid anhydrides and acid chlorides, sulfonyl chlorides and the diester of a phosphoric acid chloride and where R_1 , R_2 , R_3 and R_4 are as hereinbefore defined with R_1 - R_4 having been introduced into the structure via the acylating agent or they may be present in the starting material and n can be a number from 1-4.

An acylating anhydride may be employed without the need of an acid-binding agent. However, when acid chlorides are used in the acylation process, a non-basic acid-binding agent is employed to prevent major formation of bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde dihydrochloride as an undesired by-product. A convenient non-basic acid-binding agent which is used for this purpose is N,O-bis(trimethylsilyl) acetamide.

In accordance with the above reaction scheme, bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde dihydrochloride or an N,N'-dialkyl derivative (4) [as disclosed in U.S. Patent 4,258,181,] is treated with an aqueous solution of sodium carbonate and is allowed to stand for several hours to precipitate the free base compound (labelled (3) in the reaction scheme). The product is collected by filtration, then dried in vacuo at about 110°C for about 15 hours.

When the acylating agent A is an anhydride such as butyric anhydride, succinic anhydride, glutaric anhydride or 1,2-cyclohexane dicarboxylic anhydride and the like, the following procedure applies: The dried free base (3) is suspended and stirred in a dried solvent such as dichloromethane or N,N-dimethylformamide and the like, in an inert atmosphere, e.g., under nitrogen or argon and the like, then an excess of the anhydride (2) is added and stirring is continued until the solid is dissolved. The solution is allowed to stand at about 23°C for 8-48 hours. The product (1) precipitates either spontaneously or after addition of ether or water, then is collected by filtration.



When the acylating agent (2) is an acid chloride such as benzoyl chloride, methoxyacetyl chloride, *p*-hexylbenzoyl chloride, *m*-nitrobenzoyl chloride, 2-furoyl chloride or diethyl chlorophosphate and the like, the following procedure is used: The dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracene-dicarboxaldehyde free base (3) is suspended and stirred in dichloromethane or the like, under argon or nitrogen in a closed round bottom flask equipped with a stirrer and a rubber septum cap, then an acid binding agent such as *N,O*-bis(trimethylsilyl)acetamide is added with stirring, using a weighed hypodermic syringe to inject the reagent through the rubber septum. Then the desired acid chloride is added in the same manner. The reaction mixture is stirred from three to sixty-four hours. The solution or suspension is chromatographed by dry column chromatography on alumina, and eluted with solvents such as dichloromethane, ethyl acetate, chloroform, acetone and the like. The cuts are collected and evaluated by thin layer chromatography on silica gel using solvent systems such as 3/1, 19/1 or 39/1 of chloroform/methanol, then the cuts containing the desired products are evaporated and purified by conventional means.

When, for example, the alkyl esters of mono- and di-phosphinic acid derivatives are to be converted to the corresponding free phosphonic acids, in an elegant modification according to this invention, a triarylphosphine, preferably triphenylphosphine will be used with the cleaving agent, e.g. iodotrialkylsilane, to remove byproduct alkyl iodide, thus precluding alkylation in other positions. This will be exemplified hereinafter.

Certain in vivo testing systems and protocols have been developed by the National Cancer Institute for testing compounds to determine their suitability as

antineoplastic agents. These have been reported in "Cancer Chemotherapy Reports", Part III, Vol. 3, No. 2 (1972), by Deran, Greenberg, MacDonald, Schumacher and Abbott. These protocols have established standardized screening tests which are generally followed in the field of testing for antitumor agents. Three of these systems are particularly significant to the present invention. They are lymphocytic leukemia P388, melanotic melanoma B16 and lymphocytic leukemia L1210. All of these neoplasms grow in mice. Generally, good antitumor activity, shown in these protocols by a percentage increase of mean survival times of the treated (T) animals over the control (C) animals, is predictive of similar results in human leukemias.

15 Lymphocytic leukemia P388 test

The animals used were BDF1 mice all of one sex per test, weighing a minimum of 17 g and all within a 3 g weight range per test. There were 6 animals per test group. The tumor transplant was by intraperitoneal injection of 0.5 ml of diluted ascitic fluid containing 10^6 cells of lymphocytic leukemia P388. The test compounds were administered intraperitoneally on days 1, 5 and 9 (relative to tumor inoculation) at various doses. The animals were weighed and survivors recorded on a regular basis for 60 days. The median survival time and the ratios for treated (T)/control (C) animals were calculated. The positive control compound was either 5-fluorouracil, given as a 60 mg/kg injection, or bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde dihydrochloride hereinafter called positive control A or B, respectively given as a 25 mg/kg injection. The results of this test with representative compounds of the present invention appear in Table I.

TABLE I
Lymphocytic Leukemia P388 Test

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
2-[[10-[[Acetyl(1-acetyl- -4,5-dihydro-1H-imidazol- 2-yl)hydrazono[methyl]-9- anthracenyl]methylene]-1- (4,5-dihydro-1H-imidazol- 2-yl)hydrazide of acetic acid	200 100 50 25 12.5 6.25	17.5 17 16.5 15.5 13 12.5	175 170 165 155 130 125
Control	-	10	-
Positive Control B	25	21.5	215
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro-1-(1- oxobutyl)-1H-imidazole	200 100 50 25 12.5	15.5 14.5 14 12.5 12.5	155 145 140 125 125
Control	-	10	-
Positive Control B	25	21.5	215
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro-gamma- oxo-1H-imidazole-1-but- anoic acid]	12.5 6.25 3.12 1.56 0.78 0.39 0.19	23 19 19 17 17 15.5 15	230 190 190 170 170 155 150
Control	-	10	-
Positive Control A	60	17.5	175
[9,10-Anthracenediylbis [methylidyne-1-hydra- zinyl-2-ylidene(4,5-di- hydro-1H-imidazol-2,1- diyl)]]bisphosphonic acid, tetraphenyl ester	200 100 50	16 15.5 13	160 155 130
Control	-	10	-
Positive Control A	60	17.5	175

TABLE I (continued)

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
[9,10-Anthracenediylbis [methylidyne-1-hydra- ziny1-2-ylidene(4,5-di- hydro-1H-imidazole-2,1- diyl)]]bisphosphonic acid, tetraethyl ester	100	12	120
Control	-	10	0
Positive Control A	60	17.5	175
[9,10-Anthracenediylbis [methylidyne-1-hydra- ziny1-2-ylidene(4,5-di- hydro-1H-imidazole-2,1- diyl)]]bisphosphonic acid	25 12.5 6.25 3.12 1.56 0.78	36.5 27.5 22 18 17 17.5	365 275 220 180 170 175
Control	-	10	-
Positive Control A	60	17.5	175
2,2'-(9,10-Anthracene- diyl)dimethylidyne)bis- [1-(1-benzoyl-4,5-dihydro 1H-imidazol-2-yl)hydra- zide] of benzoic acid	200 100 50 25 12.5 6.25 3.12 1.56 0.78	32 23 20 19.5 19 13 17 17.5 15.5	320 320 200 195 190 180 170 175 155
Control	-	10	-
Positive Control A	60	23	230
2,2'-9,10-Anthracene- diyl)dimethylidyne)bis[1- [4,5-dihydro-1-(methoxy- acetyl)-1H-imidazol-2- yl]hydrazide] of meth- oxyacetic acid	200 50 12.5 3.12	16.5 16.5 16.5 14.5	150 150 150 132
Control	-	11	-
Positive Control B	25	32.5	295

TABLE 1 (continued)

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)]bis [4,5-dihydro- <u>delta</u> -oxo- 1H-imidazole-1-pentanoic acid]	200 50 12.5 3.12	23 19 18 15.5	209 173 164 141
Control	-	11	-
Positive Control B	25	32.5	295
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro-1-[(4- methylphenyl)sulfonyl]- 1H-imidazole]	200 50	14 14	127 127
Control	-	11	-
Positive Control A	25	32.5	295
2,2'-(9,10-Anthracene- diyl(dimethylidyne)bis[1- [1-(4-hexylbenzoyl)-4, 5-dihydro-1H-imidazol- 2-yl]hydrazide] of 4- hexylbenzoic acid	200	14	127
Control	-	11	-
Positive Control A	60	20	182
2,2'-(Anthracenediyl- dimethylidyne)bis[1- [4,5-dihydro-1-(3-ni- trobenzoyl)-1H-imidazol- 2-yl]hydrazide] of 3- nitrobenzoic acid	200 100 50 25 12.5 6.25 3.12	21.5 18 16.5 18 13.5 16 16	179 150 138 150 113 133 133
Control	-	12	-
Positive Control A	60	21.5	-

TABLE I (continued)

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
2,2'-(9,10-Anthracene- diyl dimethylidene)bis[1- [4,5-dihydro-1-(4-meth- oxybenzoyl)-1H-imidazol- 2-yl]hydrazide] of 4- methoxybenzoic acid	200	16	139
Control	-	11.5	-
Positive Control B	25	16	139
2,2'-[9,10-Anthracene- diylbis(methylidene-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro-1H-im- dazole-1-carboxylic acid], bis(1,1-dimethylethyl) ester	50 25 12.25	31.5 22 17.5	274 191 152
Control	-	11.5	-
Positive Control B	25	16	139
2,2-(Anthracenediyl- dimethylidene)bis[1- [1-(2-furanylcarbonyl) -4,5-dihydro-1H-imidazol -2-yl]hydrazide] of 2- furancarboxylic acid	200	12	120
Control	-	10	-
Positive Control A	60	17	170
2,2'-[9,10-Anthracene- diylbis(methylidene-1- hydrazinyl-2-ylidene) bis[4,5-dihydro-1H-im- dazol-1-carboxaldehyde]	200 50	12 12	120 120
Control	-	10	-
Positive Control A	60	17	170

TABLE I (continued)

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene(4, 5-dihydro-1H-imidazole -2,1-diyl)carbonyl)] biscyclohexanecarboxy- lic acid	25 12.5 6.25	18 16 13.5	164 145 123
Control	-	11	-
Positive Control B	25	33	300
2,2'-(9,10-Anthracene- diyl(dimethylidyne)bis[1- [1-(3,3-dimethyl-1-oxo- butyl)-4,5-dihydro-1H- imidazol-2-yl]hydra- zide] of 3,3-dimethyl butanoic acid	200 100	13 12	118 109
Control	-	11	-
Positive Control A	60	20	182
2,2'-(9,10-Anthracene- diyl(dimethylidyne)bis [1-[4,5-dihydro-1- (1-oxobutyl)-1H-im- idazol-2-yl]hydrazide] of butanoic acid	200	11.5	105
Control	-	11	-
Positive Control B	25	32.5	295
2,2'-[9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)] bis[1-acetyl-4,5-dihydro- 1H-imidazole]	50 25 12.5 6.25	11 10.5 10.5 10.5	110 105 105 105
Control	-	10	-
Positive Control A	60	11.5	115

TABLE I (continued)

Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
2,2'-(9,10-Anthracene- diylldimethylidyne)bis	100	11	110
[1-(1-acetyl-4,5-dihydro- 1H-imidazol-2-yl)hydrazide]	50	10.5	105
of acetic acid	12.5	10.5	105
Control	-	101	-
Positive Control A	60	23	230
2,2'-(9,10-Anthracene- diylldimethylidyne)bis[1- [1-(2-fluorobenzoyl)-4,5- dihydro-1H-imidazol-2-yl] hydrazide] of 2-fluoro- benzoic acid	200 100 50 25	12 13 13 12	109 118 118 109
Control	-	11	-
Positive Control A	60	20	182
2,2'-[9,10-Anthracene- diylbis[methylidyne(1- formyl-1-hydrazinyl-2- ylidene)]]bis-[4,5-di- hydro-1H-imidazole-1- carboxaldehyde]	200 50 12.5	11.5 11 10.5	115 110 105
Control	-	10	-
Positive Control A	60	17	170
2,2'-(9,10-Anthracene- diylldimethylidyne)bis[1- [4,5-dihydro-1-(2-naphtha- lenylcarbonyl)-1H-imidazol- 2-yl]hydrazide] of 2- naphthoic acid	100	12	104
Control	-	11.5	-
Positive Control B	12.5	19	165

TABLE I (continued)

	Compound	Dose (mg/Kg)	Median Survival (Days)	T/C x 100 %
5	2,2'-(9,10-Anthracene- diylldimethylidyne)bis	200	14.5	132
	[1-[1-(4-cyanobenzoyl)- 4,5-dihydro-1H-imidazol	100	14.5	132
	-2-yl]hydrazide] of 4-	50	12.5	114
10	cyanobenzoic acid	25	12	109
	Control	-	11	-
	Positive Control A	60	20	182
15	2,2'-(9,10-Anthracene- diylldimethylidyne)bis[1-	200	12	109
	[4,5-dihydro-1-(penta- fluoro-1H-imidazol-2-			
	yl]hydrazide] of penta-			
	fluorobenzoic acid			
20	Control	-	11	-
	Positive Control A	60	20	182
25	[2-[[[10-[[4,5-dihydro- 1H-imidazol-2-ylethyl- hydrazono]methyl]-9-	50	25.5	232
	anthracenyl]methylene]	25	25	227
	hydrazino]-4,5-dihydro-	12.5	25	227
	-1H-imidazol-1-yl]phos-	6.3	24	218
	phonic acid, hydroiodide	3.2	22.5	205
		1.6	18	164
		0.8	21.5	195
		0.4	18	164
	Control	-	11	-
	Positive Control A	60	22	200
30	[2[[[10-[[4,5-dihydro- 1H-imidazol-2-yl]hydra-	25	>60	>545
	zono]methyl]9-anthra-	12.5	>47	>427
	cenyl]methylene]hydra-	6.3	22	200
	zino]-4,5-dihydro-1H-	3.2	24	218
35	imidazol-1-yl]phosphonic	1.6	24.5	223
	acid, hydroiodide	0.8	19	173
		0.4	21	191
	Control	-	11	-
	Positive Control A	60	22	200

TABLE I (continued)

	Compound	Dose (mg/Kg)	Median Survival (Days)	T/C x 100 %
5	[2-[[[10-[[4,5-di-	100	>34	>309
	hydro-1H-imidazol-2-	50	>38	>345
	yl)hydrazono]methyl]-	25	>29	>264
	9-anthracenyl]methy-	12.5	19	173
	lene]hydrazino]-4,5-	6.3	21.5	195
10	dihydro-1H-imidazol-	3.2	23.5	214
	1-yl]phosphonic acid,	1.6	22.5	205
	diethyl ester	0.8	19	173
		0.4	18	164
15	Control	-	11	-
	Positive Control A	60	22	200

Melanotic Melanoma B16

5 The animals used were BDF1 mice, all of one
sex, weighing a minimum of 17 g, and all within a 3 g
weight range. There were normally 12 animals per test
group, and 18 animals per control group. A one gram
portion of melanotic melanoma B16 tumor was homogenized
in 10 ml of Eagle's Minimum Essential Medium, supplemented
with 2% fetal calf serum, and a 0.5 ml aliquot of the
homogenate was implanted intraperitoneally into each
10 test mouse. The test compounds were administered
intraperitoneally on days 1, 5 and 9 (relative to tumor
inoculation) at various doses. The animals were weighed
and survivors recorded on a regular basis for 60 days.
The median survival time and the ratio of survival time
15 for treated (T)/control (C) animals were calculated.
The positive control compound was bis(2-imidazolin-2-
ylhydrazone) of 9,10-anthracenedicarboxaldehyde dihyd-
rochloride (hereinafter called positive control) given
as intraperitoneal injection at a dose of 25 mg/kg on
20 days 1, 5 and 9 (relative to tumor inoculation). The
results of this test with representative compounds of
the present invention appear in Table II.

TABLE II
Melanotic Melanoma B16 Test

	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
5	2,2'-(9,10-Anthracene- diylbis(methylidyne-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro- <u>gamma</u> oxo-1H-imidazole-1- butanoic acid]	12.5 6.25 3.25	55.5 >60 >60	252 >273 >273
10	Control Positive Control B	- 25	22 27	- 123
15	[9,10-Anthracenediylbis- [methylidyne-1-hydra- zinyl-2-ylidene(4,5-di- hydro-1H-imidazole-2,1- diyl)]]Bisphosphonic acid	25 6.25 1.56	37.5 35.5 29	163 154 126
20	Control Positive Control B	- 25	23 53	- 230
25	2,2'-(9,10-Anthracenediyl- dimethylidyne)bis[1-(1- benzoyl-4,5-dihydro-1H- imidazol-2-yl)hydrazide] of benzoic acid	200 100 50 25 12.5	50 57.5 40 32 29.5	227 261 182 145 134
	Control Positive Control B	- 25 12.5	22 57.5 >60	- 261 >273
30	2-[[10-[[Acetyl(1-ace- tyl-4,5-dihydro-1H- imidazol-2-yl)-hydra- zono]methyl]-9-anthracenyl] methylene]-1-(4,5-dihydro- 1H-imidazol-2-yl)-hydrazide of acetic acid.	200 100 50 25 12.5	40 37 29.5 30 28	182 168 134 136 127
35	Control Positive Control B	- 25 12.5	22 57.5 >60	- 261 >273

TABLE II (continued)

	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
5	2,2'-[9,10-Anthracene- diylbis(methylidene-1- hydrazinyl-2-ylidene)] bis[4,5-dihydro-1-(1- oxobutyl)-1H-imidazole]	200	27.5	125
		100	28.5	130
		50	24.5	111
		25	26	118
10	Control	-	22	-
	Positive Control B	25	57.5	261
		12.5	>60	>273

Lymphocytic Leukemia L1210 Test

- 15 The animals used were BDF1 mice, all of one sex, weighing a minimum of 17 g and all within a 3 g weight range. There were 6 mice per test group and 18 in control groups. The tumor transplant was by intraperitoneal injection of 0.5 ml of diluted ascites containing 10^5 viable L1210 leukemia cells per mouse.
- 20 The test compounds were administered intraperitoneally on days 1, 5 and 9 (relative to tumor inoculation) at various doses. The animals were weighed and survivors recorded on a regular basis for 30 days. The mean survival time and the ratio of survival time for treated
- 25 (T)/control(C) animals were calculated. The positive control compound was 5-fluorouracil given intraperitoneally at 60 mg/kg. The results of this test appear in Table III.

TABLE III
Lymphocytic Leukemia L1210 Test

	Compound	Dose (mg/kg)	Median Survival (Days)	T/C x 100 %
5				
	2,2'-[9,10-Anthracene-	12.5	13.2	155
	diylbis(methylidyne-1-	6.25	12.2	144
	hydrazinyl-2-ylidene)]	3.12	12.3	145
	bis[4,5-dihydro-gamma-	1.56	12	141
10	oxo-1H-imidazole-1-	0.78	11.2	132
	butanoic acid]	0.39	11.5	135
	Control	-	8.5	-
	5-Fluorouracil A	60	16.8	198
15	[9,10-Anthracenediyl-	25	17	200
	bis[methylidyne-1-hydr-	12.5	13.3	156
	azinyl-2-ylidene(4,5-	6.25	13.2	155
	dihydro-1H-imidazole-2,	3.12	12.2	144
	1-diyl)]Bisphosphonic	1.56	11.5	135
	acid	0.78	10.7	126
20	Control	-	8.5	-
	Positive Control A	60	16.8	198

Also embraced within the purview of the present invention are therapeutic compositions of matter useful for ameliorating cancer diseases in mammals which contain the acylation products of the present invention as the active ingredients thereof.

This aspect of the invention includes the compositions of matter and the method of inducing the regression and/or palliation of leukemia and related cancers in mammals, when administered in amounts ranging from about 0.075 mg to about 300 mg per square meter of mammalian body surface area per day. The interrelationship of dosages for animals of various sizes and species and humans (based on mg/m^2 of surface area) is described

by Freireich, E.J., et al., Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man, Cancer Chemother. Rep., 50, No. 4, 219-244, May 1966. A preferred dosage regimen for optimum results would be from about 3.0 mg/m²/day to about 150 mg/m²/day. Such dosage units are employed that a total of from about 0.5 mg to about 525 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period. This dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The active compound may be administered by the intravenous, intramuscular, or subcutaneous routes.

The active compounds may be administered parenterally or intraperitoneally. Solutions or dispersions of the active compound can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for

example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for
5 example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal
10 agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases it will be preferable to include isotonic agents, for example sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by
15 the use in the compositions of agents delaying absorption, for example aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount
20 in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the
25 basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying
30 technique which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion
35 media, coatings, antibacterial and antifungal agents,

isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically-acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from about 0.1 to about 500 mg, with from about 10 to about 500 mg being preferred. Expressed in proportions, the active compound is generally present in from about 0.1 to about 100 mg/ml of carrier. In the case of compositions

containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

Regression and palliation of cancers are
5 attained, for example, using intraperitoneal administration. A single intravenous dosage or repeated daily dosages can be administered. Daily dosages up to about 5 to 10 days are often sufficient. It is also possible to dispense one daily dosage or one dose on alternate or
10 less frequent days. As can be seen from the dosage regimens, the amount of principal active ingredient administered is a sufficient amount to aid regression and palliation of the leukemia or the like, in the absence of excessive deleterious side effects of a cytotoxic nature to the hosts harboring the cancer. As used
15 herein, cancer disease means blood malignancies such as leukemia, as well as other solid and non-solid malignancies such as the melanocarcinomas, lung carcinomas, and mammary tumors. By regression and palliation is meant arresting or retarding the growth of the tumor or
20 other manifestation of the disease compared to the course of the disease in the absence of treatment.

The clinical use of some anti-tumor agents, particularly anthracene derivatives, has been reported
25 to be accompanied by a painful phlebitis in some patients near the site of injection. This phlebitis appears to be associated with the precipitation of the free base of the agent within the blood vessel due to basification of its acid addition salts e.g., the
30 hydrochloride salt, by the blood.

It has now been discovered that the di- and most notably, the monophosphoramidic acid derivatives of the antitumor compound, bisantrene, provided by this invention exhibit excellent clinical efficacy without
35 the attendant phlebitis - precipitation problems seen in

the prior art. Both of these derivatives exist as soluble anionic salts at physiological pH, i.e., 7.4. This enhanced solubility apparently reduces if not eliminates altogether any phlebitis reaction near the
5 site of injection. As will be described in the following section, no precipitation of the monophosphoramidic acid compound is detected in a rat tail-vein model.

In the rat, the diphosphoramidic compound was found to be a pro-drug for bisantrene. The diphosphor-
10 amidic compound hydrolyzes rapidly to an intermediate form, the monophosphoramidic acid, and this, in turn, slowly hydrolyzes further to bisantrene after distribution of the drug throughout the animal. These in vivo hydrolyses are apparently enzymatic because the
15 diphosphoramidic compound has been shown to be much more stable in water. Furthermore, the stability in water is more than adequate for an efficient formulation via lyophilization.

This invention will be described in greater
20 detail in conjunction with the following specific examples.

Example 1

Bis(2-imidazolin-2-ylhydrazine) of 9,10-anthracene-
dicarboxaldehyde

25 To a solution of 60.0 g of bis(2-imidazolin-2-ylhydrazine) of 9,10-anthracenedicarboxaldehyde dihydrochloride (prepared as described in U.S. Patent 4,258,181) in 1400 ml of water was added a solution of 27.0 g of sodium carbonate in 400 ml of water, with vigorous
30 swirling. The resulting suspension was allowed to stand 5 hours, then the solid was collected in a three-liter, coarse porosity sintered glass funnel and washed with three 1.2 liter portions of very dilute aqueous ammonia, at a concentration of 2.0 ml of concentrated ammonia per
35 liter. The ammonia solution enabled satisfactorily

rapid filtration by lowering surface tension and preventing peptiation of the solid. The last wash was chloride-free and gave 47.2 g of the desired product as a light orange solid, mp 307-308°C.

Example 2

2,2'-(9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene))bis(4,5-dihydro-1-(1-oxobutyl)-1H-imidazole]

To a stirred suspension of 3.19 g of bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde dried in vacuo at about 110°C for about 15 hours; in 100 ml of N,N-dimethylformamide (dried over 4A molecular sieves), was added 12.66 g of butyric anhydride. All of the solid was dissolved after stirring for 20 minutes. The solution was filtered through a sintered glass funnel. the filtrate was allowed to stand 26 hours at about 23°C as a crystalline solid separated. The solid was collected by filtration, washed with N,N-dimethylformamide, then with ether to give 1.72 g of the desired product as orange needles.

EXAMPLE 3

2,2'[9,10-Anthracenediylbis(methylidene-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-gamma-oxo-1H-imidazole-1-butanoic acid]

A suspension of 3.19 g of bis(2-imidazolin-2-yl-ydrazone) of 9,10-anthracenedicarboxaldehyde (dried in vacuo at 111°C for 15 hours) and 4.80 g of succinic anhydride in 100 ml of dried N,N-dimethylformamide was stirred for 40 minutes, when the solid had dissolved. the hazy solution was filtered and the filtrate allowed to stand at 23°C for 24 hours. The filtrate was diluted with 500 ml of water and the resulting slightly warm solution was immediately chilled in an ice bath, producing small granular orange crystals and a finely divided yellow colloid. The colloid was decanted and

the granular crystals were washed four times by decantation with cold water, then collected by filtration to give 2.84 g of the desired product as an orange solid, mp 129-133°C.

5

Example 4

[9,10-Anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)]]bis-phosphonic acid, tetraethyl ester

10 To a stirred suspension of 7.969 g of dried bis-(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedi-carboxaldehyde in 400 ml of dried dichloromethane under argon was added with stirring via hypodermic syringes and a rubber septum, first 8.137 g of N,O-bis(trimethyl-silyl)acetamide, then 6.902 g of diethyl chlorophos-
15 phate. The solid all dissolved after stirring for about 3 hours. The solution was filtered through 200 g of dry-packed, air-equilibrated neutral alumina, (ICN, "for dry-column chromatography") in a 3.8cm x 18cm column. The colored part of the eluate was collected (cut 1) and
20 the column was eluted with an additional 5 x 200 ml of dichloromethane to obtain cuts 2-6. Cuts 1-4 were combined and concentrated to 40 ml, then 100 ml of toluene was gradually added to the boiling mixture, with swirling, as a crystalline solid separated and the volume
25 boiled down to 100 ml with bp 100°C. The solid which crystallized was washed with toluene, then with methanol to give 4.36 g of the desired product as orange needles, mp 217°C.

Example 5

30 [9,10-Anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)]]bis-phosphonic acid, tetraphenyl ester

To a stirred suspension of 1.99 g of dried bis-(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedi-
35 carboxaldehyde in 100 ml of dried dichloromethane were

added, under argon as described in Example 4, 2.03 g of N,O-bis(trimethylsilyl)acetamide "BSA" and 2.68 g of diphenyl phosphorochloridate. After one hour of stirring all of the solid had dissolved. Stirring was continued for 2 hours longer. The reaction solution was poured into a 3.8cm x 18cm dry column of 200 g of air-equilibrated alumina. The column was developed with dichloromethane and the first 100 ml of colorless eluate was discarded, then as the first yellow band neared the bottom, elution cuts of 100 ml each were collected and evaporated. The residue from the first cut, 1.74 g, was dissolved in about 13 ml of dichloromethane, then 40 ml of toluene was added and the solution was heated to boil off the dichloromethane, reduce the volume to about 25 ml and crystallize a solid. The solid was collected by filtration and washed with toluene, then with ether to give 1.65 g of the desired product as an orange solid, mp 214-215°C.

Example 6

[9,10-Anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)]]bis-phosphonic acid

To a stirred orange solution of 8.74 g of the tetraethyl ester of [9,10-anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)]]-bis phosphonic acid in 150 ml of dried dichloromethane under argon was added 13.0 g of iodotrimethylsilane via a glass hypodermic syringe and rubber septum. There was a slight exothermic reaction to about 40°C and the solution became yellow. Within 5 minutes it was orange again. After 30 minutes the solution was evaporated to dryness in vacuo. The glassy residue solidified when suspended in 150 ml of acetone containing 5.2 ml of water to hydrolyze the intermediate silyl ester. The suspension was stirred for 16 hours. The

solid was collected and washed with acetone to give 8.17 g of yellow solid. This solid was recrystallized by dissolving it in 200 ml of triethylamine, thus forming a soluble phosphoramidic acid salt. The free phosphoramidic acid was precipitated by adding 1.82 ml of 97% formic acid. The solid was collected by filtration and washed with ethanol to give 6.04 g of yellow solid which turned orange when dried, mp 235-238°C.

Example 7

2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-(1-benzoyl-4,5-dihydro-1H-imidazol-2-yl)hydrazide]
of benzoic acid

The procedure of Example 4 was followed while reacting 1.99 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde, 2.034 g of N,O-bis(trimethylsilyl)acetamide and 1.406 g of benzoyl chloride in 100 ml of dried dichloromethane. The suspension was stirred for 2 days at 24°C and then was filtered to remove some insoluble orange solid which was washed with dichloromethane. The filtrate and washes were passed through 50 g of air-equilibrated alumina in a 2.3cm x 13.0cm column. The initial colorless eluate was collected as cut 1. Further elution with dichloromethane gave 50 ml each of cuts 2-5. The eluates were evaporated and the residues from cuts 1 and 2 were washed with ether and combined to give 1.205 g of the desired product as an orange solid, mp 111-114°C.

Example 8

2,2'-[9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-delta-oxo-1H-imidazole-1-pentanoic acid]

A mixture of 3.19 g of bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde and 5.48 g of glutaric anhydride in 100 ml of dried N,N-dimethyl-

formamide was stirred at 24°C for 23 hours. The solution was evaporated in vacuo at 35°C. The residue was diluted with 20 ml of dry N,N-dimethylformamide and swirled to dissolve the residue, then 100 ml of dry ether was added and the mixture was swirled and allowed to stand for several hours. The precipitate which formed was collected and washed with ether to give 4.81 g of the desired product as an orange solid, mp 218-221°C.

Example 9

10 2,2'-[9,10-Anthracenediylbis(methyldi-
2-ylidene)]bis[4,5-dihydro]-1H-imidazole-1-
carboxaldehyde

To a stirred suspension of 3.98 g of dried bis-(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedi-
15 carboxaldehyde in 50 ml of dried N,N-dimethylformamide was added 10.0 ml of phenyl formate. Stirring was continued for 37 hours at 21°C; the red-orange suspension had gradually changed to yellow in the first hour. Filtration and washing with acetone gave 4.61 g
20 of the desired product as a yellow solid, mp 280-281°C.

Example 10

2,2'-[9,10-Anthracenediylbis(methyldi-
2-ylidene)]bis[4,5-dihydro]-1H-imidazole-1-carboxylic
acid], bis(1,1-dimethylethyl) ester

25 To a solution of 6.55 g of di-tert-butyl dicarbonate in 100 ml of dry N,N-dimethylformamide was added 3.98 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde. The suspension was protected with a drierite tube (to allow by-product
30 carbon dioxide to escape) and was stirred at 22°C for 15 hours to give a yellow solution. A 60 ml portion of water was added to the solution until the first sign of turbidity. A clear gum (A) gradually separated. After standing for 2 hours the supernatant was decanted from
35 the gum and filtered through a filter paper cone over

about 16 hours. The filtrate gradually deposited orange crystals. After 24 hours the crystals were collected and washed twice with N,N-dimethylformamide/water, 25/10, then twice with water to give 1.29 g of yellow solid (B). The gum (A) crystallized on standing and this material was washed as for (B) above to give 0.59 g of yellow solid (C). The combined clear filtrate and the N,N-dimethylformamide/water wash from (B) above was diluted to 300 ml with water. The resulting emulsion was allowed to stand for 15 hours, then the agglomerated material was collected by filtration and washed with water to give 3.06 g of a yellow solid (D). A solution of combined yellow solids (B) and (C) 1.68 g in 10 ml of dichloromethane was chromatographed on 8.40 g of neutral alumina (ICN, "for dry-column chromatography") in a 1.0cm x 8.0cm column, eluting with dichloromethane until the yellow band eluted. Evaporation of the eluate gave 1.81 g of a yellow glass. The glass was covered with 30 ml of petroleum ether and mixed, then was allowed to stand for 16 hours. The material recrystallized and was collected by filtration, and washed with ether to give 1.37 g of bis-(1,1-dimethylethyl)2,2'-[9,10-anthracene-diylbis[methyldiylne[1-[(1,1-dimethylethoxy)carbonyl-1-hydrazinyl-2-ylidene]]bis[4,5-dihydro-1H-imidazole-1-carboxylate] as a yellow solid, mp 190-191°C.

A 2.94 g amount of the yellow solid (D) was washed three times with ether leaving 1.84 g of an orange solid. The orange solid (1.84 g) was pulverized and triturated with 50 ml of dichloromethane, the filtered. The orange solid on the filter was washed with dichloromethane. The filtrate and washes were combined and repeatedly refiltered through a pad of diatomaceous earth, then the filtrate was subjected to dry column chromatography on 200 g of air equilibrated silica gel (ICN Co., "for dry-column chromatography") in

a 3.4 x 50.0cm nylon column, developing the column with 200 ml of chloroform/methanol, 19/1. The fastest yellow band moved only to Rf 0.35 as solvent reached the bottom. The following bands were cut out and extracted on small fritted-glass funnels with chloroform/methanol, 3/1, and the extracts were evaporated to obtain the residues.

Extract No.	RF of Band on Column (Color)	Residue Wt. and Color
10		Yellow
1	0.0 -0.05(tan)	0.02 g Solid
2	0.06-0.15(light orange)	0.03 g Pale orange solid
15		Orange
3	0.16-0.25(light yellow)	0.44 g solid
4	0.26-0.35(orange tan)	0.81 g Orange solid

The residue of extract 4, 0.81 g was dissolved in 5.0 ml of dichloromethane, then was filtered and the filtrate evaporated to give a glassy residue. The residue was swirled with about 20 ml of ether and allowed to stand. Then the solid was collected and washed with ether to give 0.50 g of the desired product as a yellow orange solid, mp 148-151°C.

25

Example 11

2,2'-(9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene))bis[4,5-dihydro-1-[(4-methylphenyl)-sulfonyl]-1H-imidazole]

The procedure of Example 4 was followed while reacting 1.99 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde, 2.034 g of N,O-bis-(trimethylsilyl)acetamide and 1.91 g of p-toluenesulfonyl chloride in 100 ml of dried dichloromethane. The suspension was stirred at 24°C for 44 hours, then was filtered to remove some insoluble orange solid, and

washed with dichloromethane. The filtrate and washes were passed through 50.0 g of air-equilibrated alumina. The initial colorless eluate was discarded and additional dichloromethane was added as seven 50 ml cuts were collected. The first two cuts were evaporated and the residue washed sparingly with chloroform to give 1.10 g of the product of the example, mp 255-258°C.

Example 12

2,2'-(9,10-Anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)-carbonyl]]biscyclohexanecarboxylic acid

A suspension of 3.19 g of bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde and 5.4 g of trans-1,2-cyclohexanedicarboxylic anhydride in 100 ml of dried N,N-dimethylformamide was stirred at 24°C for 3 hours. The clear solution was concentrated in vacuo to near dryness then was slurried with 100 ml of ether. The solid that formed was collected by filtration, washed with ether and dried in vacuo to give 6.7 g of the desired product.

Example 13

2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(methoxyacetyl)-1H-imidazol-2-yl]-hydrazide] of methoxyacetic acid

The procedure of Example 4 was followed while reacting 1.99 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde, 4.069 g of N,O-bis-(trimethylsilyl)acetamide and 2.17 g of methoxyacetyl chloride in 100 ml of dried dichloromethane. The reaction mixture was allowed to stir at room temperature for 64 hours, then was filtered to remove some unreacted material and washed with dichloromethane. The filtrate and washes were chromatographed through 50 g of Bio Sil A (Bio-Rad Laboratories). The column was eluted first with 150 ml of dicloromethane for cuts 1 and 2, 250 ml

of dichloromethane with 2% methanol for cuts 3 and 4, 100 ml of dichloromethane with 3% methanol for cuts 5 and 6, 100 ml of dichloromethane with 4% methanol for cut 7 and 100 ml of dichloromethane with 5% methanol for cut 8. The cuts were made by using visual observation to separate the three bands on the column. The cuts were evaporated in vacuo. The residue from cut 5 (1.635 g), derived from the largest (middle) band, was recrystallized from dichloromethane/tert-butyl methyl ether to give the desired product as a fine yellow powder, mp 225-229°C.

Examples 14 - 24

Additional acid chloride acylation products of bis(2-imidazolin-2-ylhydrazine) of 9,10-anthracene-dicarboxaldehyde listed in Table IV were prepared in the manner described by the procedures of Examples 4, 5 and 13, reacting the given acid chloride with 5 mmol of the above base compound in the presence of an acid binding agent such as N,O-bis(trimethylsilyl)acetamide in a dried solvent such as dichloromethane or N,N-dimethylformamide with stirring for 12-74 hours, then employing column chromatography on alumina (neutral), Bio Sil A or silica gel and elution with a solvent such as dichloromethane, dichloromethane/methanol, acetone and the like to separate the desired product.

22 10 87 00033

TABLE IV

Ex.	Acid chloride	Product Name	Yield(g)	MP°C
14	4-hexylbenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[1-(4-hexylbenzoyl)-4,5-dihydro-1H-imidazol-2-yl]hydrazide] of 4-hexylbenzoic acid	4.347	83-98
15	3-nitrobenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(3-nitrobenzoyl)-1H-imidazol-2-yl]hydrazide] of 3-nitrobenzoic acid	1.913	162-175
16	2-furoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[1-(2-furanylcarbonyl)-4,5-dihydro-1H-imidazol-2-yl]hydrazide] of 2-furancarboxylic acid	2.310	210-213
17	4-methoxybenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(4-methoxybenzoyl)-1H-imidazol-2-yl]hydrazide] of 4-methoxybenzoic acid	1.332	209-211
18	4-cyanobenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[1-(4-cyanobenzoyl)-4,5-dihydro-1H-imidazol-2-yl]hydrazide] of 4-cyanobenzoic acid	0.510	178-185
19	pentafluorobenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(pentafluoro-1H-imidazol-2-yl)hydrazide] of pentafluorobenzoic acid	1.190	145-150

22 10 07 00033

TABLE IV

Ex.	Acid chloride	Product Name	Yield(g)	MP°C
20	<u>tert.</u> -butyl-acetyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[1-(3,3-dimethyl-1-oxobutyl)-4,5-dihydro-1H-imidazol-2-yl]-hydrazide] of 3,3-dimethylbutanoic acid	1.682	90-99
21	2-fluorobenzoyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[1-(2-fluorobenzoyl)-4,5-dihydro-1H-imidazol-2-yl]hydrazide] of 2-fluorobenzoic acid	3.383	167-175
22	2-naphthyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(2-naphthalenylcarbonyl)-1H-imidazol-2-yl]-hydrazide] of 2-naphthoic acid	2.147	175-182
23	acetyl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-(1-acetyl-4,5-dihydro-1H-imidazol-2-yl)hydrazide] of acetic acid	1.184	233-235
24	butyryl chloride	2,2'-(9,10-Anthracenediylldimethylidyne)bis[1-[4,5-dihydro-1-(1-oxobutyl)-1H-imidazol-2-yl]hydrazide] of butanoic acid	2.220	190-193

Example 25

2,2'-[9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-1H-imidazole-1-sulfonic acid], compound with N,N-diethylethanamine (1:2)

5 To a mixture of 1.99 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde and 5.44 g of sulfur trioxide triethylamine complex was added 50 ml of dried N,N-dimethylformamide. The orange suspension was stirred at about 21°C for 25 hours. The
10 solid was collected by filtration, washed with N,N-dimethylformamide, then ether to give 2.42 g of the desired product as a light orange solid, mp 285-290°C.

Example 26

2,2'-[9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-alpha-oxo-1H-imidazole]-propanesulfonic acid]

15 When a suspension of dried bis(2-imidazolin-2-yl-hydrazone) of 9,10-anthracenedicarboxaldehyde and two equivalents of 3-sulfopropionic anhydride [M.S. Kharasch and H.C. Brown, J. Amer. Chem. Soc., 62, 925 (1940)] in
20 100 ml of dried N,N-dimethylformamide is reacted by the procedure of Example 3 the product of the example is obtained.

Example 27

25 2,2'-[9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-N,N,N-trimethyl-3-oxo-1H imidazole-1-ethanaminium]dichloride

To 3.98 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde and 5.13 g of
30 chloroacetic anhydride was added 100 ml of dried N,N-dimethylformamide. The mixture was swirled for one minute, when all solids had dissolved. After 10 minutes 45 ml of a solution of 5.0 g of trimethylamine in 100 ml of acetonitrile was added with stirring, causing a
35 slight rise in temperature. After 10 minutes a gummy

solid began to separate. After standing for 17 hours the supernatant liquid was decanted and the residual solid was washed by decantation with two 5 ml portions of N,N-dimethylformamide, then was dried in vacuo to give the desired product as an orange solid.

Example 28

2,2'-[9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[1-acetyl-4,5-dihydro-1H-imidazole

To a suspension of 1.992 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde in 100 ml of dried dichloromethane was gradually added 8.0 ml of acetic anhydride. The solid all rapidly dissolved and then a yellow solid immediately began to separate. After five hours the solid was collected and washed with dichloromethane to give 1.98 g of the desired product as a yellow solid, mp 296-299°C.

Example 29

2-[[10-[[Acetyl(1-acetyl-4,5-dihydro-1H-imidazol-2-yl)-hydrazono]methyl]-9-anthracenyl]methylene]-1-(4,5-dihydro-1H-imidazol-2-yl)hydrazide of acetic acid

To a suspension of 1.992 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde in 100 ml of dried N,N-dimethylformamide was added 5.0 ml of acetic anhydride. In 15 minutes all of the solid had dissolved and yellow crystals began to separate. After 4 hours the solid was collected and washed three times with dry N,N-dimethylformamide. The filtrate and washes were combined and evaporated in vacuo. The residue was re-evaporated three times with 10 ml portions of dry N,N-dimethylformamide, then dried finally at 60°C in vacuo to remove a trace odor of acetic anhydride. The residue was agitated with 25 ml of dichloromethane and the undissolved solids were removed by filtration. The filtrate was evaporated to give a slightly tacky, glassy residue that hardened

while standing under 25 ml of dry ether for 16 hours. The solid was collected and washed with ether to give 0.97 g of the desired product as a yellow solid, melting at 283°C.

5

Example 30

2,2'-[9,10-Anthracenediylbis[methyldiylidene(1-formyl-1-hydrazinyl-2-ylidene)]]bis[4,5-dihydro-1H-imidazole-1-carboxaldehyde]

10 A magnetically stirred suspension of 3.98 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracene-dicarboxaldehyde in 100 ml of dried N,N-dimethylformamide was maintained at 3-5°C with an ice bath during the portionwise addition, over a 5 minute period, of 8.29 g of freshly prepared trimethylacetic formic anhydride
15 [E.J. Vlietstra, et al., Res. Trav. Chim., 101, 460 (1982), kept at -80°C as a solid, then thawed just before use]. Within another 5 minutes all of the solid had dissolved to give a hazy solution. The solution was filtered and the filtrate was allowed to stand at 23°C
20 for 64 hours. The crystals which had separated were collected and washed with acetone to give 5.11 g of the desired product as yellow-orange crystals, mp 296-301°C (dec.).

Example 31

25

[S-(R*,R*)][9,10-Anthracenediylbis[methyldiylidene-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl)(1-methyl-2-oxo-2,1-ethanediyl)]]bis carbamic acid, bis(1,1-dimethylethyl)ester

30 A suspension of 3.985 g of dried bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedicarboxaldehyde in 200 ml of dried dichloromethane containing 12.068 g of tert.-butyl-oxycarbonyl-L-alanine-O-succinimide was sonicated at 18-23°C for 3 hours and then filtered, washing with dichloromethane. The filtrate was
35 chromatographed on 100 g of aluminum oxide, eluting with

dichloromethane. After the eluate became yellow, the next 225 ml was evaporated. The residue was dissolved in 200 ml of dimethylformamide at 13°C. To this was added 5.48 ml of N-methylmorpholine and then a solution of 2.25 g of glycine in 20 ml of water to destroy excess acylating agent. The resulting solution was stirred at 23°C for 40 minutes, then chilled in an ice bath and diluted with 600 ml of ice cold water. The solid was collected and washed with water, giving 4.69 g of the desired product, mp 148-155°C.

Example 32

[S-(R*,R*)][9,10-Anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[1-(2 amino-1-oxopropyl)-4,5-dihydro-1H-imidazole]tetrahydrochloride

A solution of 4.13 g of [S-(R*,R*)][9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl) (1-methyl-2-oxo-2,1-ethanediyl)]bis carbamic acid, bis(1,1-dimethylethyl)ester in 10 ml of glacial acetic acid and 20 ml of anisole was cooled in a water bath at 16°C as hydrogen chloride was bubbled in for 3 minutes. After standing for 30 minutes the solid was collected, washed with two 35 ml portions of glacial acetic acid and four times with acetone, giving 3.61 g of the desired product, mp 205-208°C.

Example 33

2,2'[9,10-Anthracenediylbis(methylidene-1-methyl-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-gamma-oxo-1H-imidazole]-1-butanoic acid

A suspension of 16.2 g of bis(2-imidazolin-2-yl-methylhydrazone) of 9,10-anthracenedicarboxaldehyde dihydroiodide in water was stirred with 12.0 g of sodium carbonate at 50-70°C for one hour, then cooled. The solid was washed with water and dried to give 9.8 g of the free base. Subsequent acylation with succinic anhydride by the procedure of Example 3 gives the title

compound as an orange solid.

Example 34

[9,10-Anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene (4,5-dihydro-1H-imidazol-2,1-diyl)]]
phosphonic acid, diethyl ester

5 To a 3 liter round bottom flask equipped with a stirring bar was added, under argon, 41.456 g of the bis(2-imidazolin-2-ylhydrazone) of 9,10-anthracenedi-
10 carboxaldehyde, (not specially dried and therefore hydrated), 2 liters of dichloromethane, 42.33 g (51.43 ml of N,O-bis(trimethylsilyl) acetamide via a syringe and 35.90 g (30.07 ml) of diethyl chlorophosphate also via a syringe. After stirring overnight, the cloudy
15 orange mixture was filtered. The filtrate was chromatographed on 1 kg of partially deactivated (air equilibrated) alumina and developed with dichloromethane. Nine 1 liter fractions were taken and partially concentrated. Fractions 1-3 gave the product of Example
20 4. Fractions 4-7 were combined and further concentrated, giving 13.31 g of solid.

A 13.01 g portion of the above solid in a fritted funnel was washed sparingly with 30, 20 and 10 ml of dichloromethane and then with water, giving 6.50 g of orange solid. This solid was mixed with 200 ml of
25 hot dichloromethane and filtered through 3 g of silica gel, washing with 40 ml of dichloromethane. The filtrate was concentrated to about 30 ml. The resulting solid was collected and washed with a minimum of cold dichloromethane and then with carbon tetrachloride,
30 giving 4.50 g of the desired product as yellow leaflets, mp 195-202°C. Thin layer chromatography on silica gel vs chloroform/methanol (9/1), gave a spot with Rf 0.3 as compared with Rf 0.6 for the product of Example 4.

Example 35

[9,10-Anthracenediylbis[methyldiyl-1-hydrazinyl-2-ylidene (4,5-dihydro-1H-imidazol-2,1-diyl)]]phosphonic acid hydroiodide

5 To a solution of 1.07 g of dried [9,10-anthracenediylbis[methyldiyl-1-hydrazinyl-2-ylidene (4,5-dihydro-1H-imidazole-2,1-diyl)]]phosphonic acid, diethyl ester and 5.25 g of triphenylphosphine in 90 ml of dried dichloromethane, under argon, was added, via a syringe,
10 1.0 g (0.71 ml) of iodotrimethylsilane. After 30 minutes, the clear orange solution was evaporated to dryness and then re-evaporated twice from 50 ml portions of dry dichloromethane. The residue was suspended in 50 ml of acetone and 1 ml of water was added, precipitating
15 an orange gum. The gum was pressed thin and allowed to stand overnight in the moist acetone under argon. The gum solidified. It was then pulverized, collected and washed with acetone, giving 1.21 g of the desired product as an orange solid; MS ((+)FAB)507(M+H); NMR (300
20 MHz, ME₂SO-d₆) δ 1.23 (t, 3, C-CH₃), 3.77 (s, NCH₂CH₂N), 3.85 (m, CH₂ of Et), 7.70 (h, 4, arom.), 8.44 and 8.49 (m, 4, arom.), 8.78 (s, 1, NH), 9.04 (s, 1, NH), 9.34 (s, 1, CH=N), 9.43 (s, 1, CH=N), 12.54 (s, 1, C=N'H⁺).

Example 36

25 [2-[[[10-[[[4,5-Dihydro-1H-imidazol-2-yl]ethylhydrazono]methyl]-9-anthracenyl]methylene]hydrazino]-4,5-dihydro-1H-imidazol-1-yl]phosphonic acid, hydroiodide

The procedure of Example 35 was followed except
30 that no triphenylphosphine was used to remove by-product ethyl iodide. A solution of the crude, solidified reaction product in 10 ml of methanol was filtered through 1 g of alumina in a 0.6 cm column, washing with 5 ml of methanol. The filtrate was evaporated almost to
35 dryness when the residual syrup began to crystallize. A

20 ml portion of acetone was added, the solid was macerated and then allowed to stand overnight. The solid was collected and washed with acetone, giving 1.057 g of the desired product; MS ((+)FAB), 479(M+H);
5 NMR (300 MHz, Me₂ SO-d₆) δ 3.77 (s, 8, NCH₂CH₂N), 7.66 (m, 4, arom.), 8.49 (h, 4, arom.), 8.79 (s, 2, NH), 8.92 (s, 1, NH), 9.34 and 9.36 (d, 2, CH=N), 12.58 (d, 1, C=N'H⁺).

Example 37

10 Disodium [9,10-anthracenediylbis [methylidyne-1-hydrazinyl-2-ylidene (4,5-dihydro-1H-imidazole-2,1-diyl)]] bis [phosphate]


To a stirred suspension of 585 mg of the compound prepared according to Example 6, [9,10-anthracenediylbis[methylidyne-1-hydrazinyl-2-ylidene (4,5-
15 dihydro-1H-imidazole-2,1-diyl)]]bisphosphonic acid in 10 ml of water, monitored by a pH meter, was added dropwise 18.3 ml of 0.1N sodium hydroxide, at a rate such that the pH never exceeded 7.5 and gave a final pH of 7.4. This solution was evaporated at 35°C over 5 hours,
20 giving 629 mg of the desired product as an amorphous red-orange solid.

The compound prepared according to Example 37 was tested in the rat tail vein model for phlebitis reaction near the site of injection. For comparison
25 purposes, a control placebo and bisantrene were also tested. The compounds were administered intravenously in an amount of 25 mg/kg. Observations were made at 1, 5 and 9 days following the injection.

No evidence of phlebitis was seen in the rat
30 tail vein model that was administered the compound prepared according to Example 37, in contrast to bisantrene which did produce evidence of phlebitis near the site of injection.

The claims defining the invention are as follows:

1. A compound of the formula:



wherein R_1 and R_3 are the same or different and are

$\text{--}\overset{\text{O}}{\parallel}\text{C--}R_5$ [where R_5 is hydrogen, alkyl(C_1 - C_6), phenyl, monosubstituted phenyl (wherein the substituent may be ortho, meta or para and is fluoro, nitro, alkyl(C_1 - C_6), alkoxy(C_1 - C_3) or cyano),

pentafluorophenyl, naphthyl, furanyl, $\text{--}\overset{\text{CH}_3}{\underset{|}{\text{CH}}}\text{NHCOOC(CH}_3)_3$,

$\text{--}\overset{\text{CH}_3}{\underset{|}{\text{CH}}}\text{NH}_2$, $\text{--CH}_2\text{CH}_2\text{COOH}$, $\text{--O--C(CH}_3)_3$, $\text{--CH}_2\text{OCH}_3$, $\text{--(CH}_2)_3\text{COOH}$,

$\text{--}\overset{\text{COOH}}{\underset{|}{\text{C}_6\text{H}_4}\text{--}}$, $\text{--(CH}_2)_2\text{SO}_3\text{H}$, $\text{--CH}_2\text{N}^+\text{--(CH}_3)_3\text{Cl}^-$] $\text{--}\overset{\text{O}}{\parallel}\text{P(OH)}_2$,

$\text{--}\overset{\text{O}}{\parallel}\text{P(OC}_2\text{H}_5)_2$, $\text{--}\overset{\text{O}}{\parallel}\text{P(O--C}_6\text{H}_4\text{--)}_2$, $\text{--SO}_2\text{--C}_6\text{H}_4\text{--CH}_3$ or $\text{--SO}_3\text{H}$;

R_2 and R_4 are the same or different and are hydrogen, alkyl(C_1 - C_4)

or $\text{--}\overset{\text{O}}{\parallel}\text{C--}R_6$ [where R_6 is hydrogen, alkyl(C_1 - C_6), phenyl, monosubstituted phenyl (wherein the substituent may be in the ortho, meta or para position and is fluoro, nitro, alkyl(C_1 - C_6), alkoxy(C_1 - C_6)

or cyano), pentafluorophenyl, naphthyl, furanyl or $-\text{CH}_2\text{OCH}_3$]; together with the pharmacologically acceptable salts thereof.

2. The compound according to claim 1, wherein only one of R_1 and R_3 may be hydrogen or alkyl(C_1-C_6).

3. The compound according to Claims 1 or 2, 2,2'-

[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-1-(oxobutyl)-1H-imidazole], 2,2'-

[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-1-gamma-oxo-1H-imidazole-1-butanoic acid]

[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl))]bisphosphonic acid, tetraethyl ester,

[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl))]bisphosphonic acid, 2,2'-[9,10-anthracenediyl(dimethylidyne)

bis[1-(1-benzoyl-4,5-dihydro-1H-imidazol-2-yl)hydrazide]

of benzoic acid, 2,2'-[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-delta-oxo-1H-imidazole-1-pentanoic acid],

2,2'-[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene)]bis[4,5-dihydro-1H-imidazole-2-carboxylic acid], bis-((1,1-dimethylethyl)ester

2,2'-[9,10-anthracenediyl(dimethylidyne)]bis[1-(4,5-dihydro-1-(3-nitrobenzoyl)-1H-imidazol-2-yl)hydrazide] of

3-nitrobenzoic acid, 2-[[10-[[acetyl(1-acetyl-4,5-dihydro-1H-imidazol-2-yl)hydrazono]-methyl]-9-anthracenyl]methylene]

-1-(4,5-dihydro-1H-imidazol-2-yl)hydrazide of acetic acid, or (R^*, R^*) [9,10-anthracenediylbis(methylidyne-1-hydrazinyl

-2-ylidene)]bis[1-(2-amino-1-oxopropyl)-4,5-dihydro-1H-imidazole] tetrahydrochloride, [9,10-anthracenediylbis

[methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl))]phosphonic acid, diethyl ester,

[9,10-anthracenediylbis(methylidyne-1-hydrazinyl-2-ylidene(4,5-dihydro-1H-imidazole-2,1-diyl))]phosphonic acid or,


[2-[[[10-[[4,5-dihydro-1H-imidazol-2-yl)ethylhydrazono]-methyl]-9-anthracenyl]methylene]hydrazino]-4,5-dihydro-1H-imidazol-1-yl]-phosphonic acid.



4. A composition of matter in dosage unit form comprising from 1 mg to 1.2 g per square meter of mammalian body surface area of a compound of any one of Claims 1 to 3 in association with a pharmaceutically acceptable carrier.

5. A method of treating tumors in warm-blooded animals which comprises administering to said animals an oncolytic amount of a compound of any one of Claims 1 to 3 or a composition of claim 4.

6. A process for preparing a compound of the formula:



wherein R_1 and R_2 , R_3 and R_4 are as defined in claim 1 or claim 2 characterized by reacting suspensions of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde in an organic solvent with an acylating agent.

7. A compound as defined in claim 1 and substantially as herein described with reference to any one of Examples 1 to 37.

8. A pharmaceutical composition for treating tumors in a warm-blooded animal comprising a compound as defined in claim 7 and a pharmaceutically acceptable carrier, diluent and/or adjuvant.

9. A process for preparing a compound as defined in claim 1 which process is substantially as herein described with reference to any one of Examples 1 to 37.



- 46 -

10. A method of treating tumors in a warm-blooded animal in need of such treatment which method comprises administering to said animal an oncolytic amount of a compound as defined in claim 7 or a composition as defined in claim 8.

DATED this NINTH day of JULY 1990
American Cyanamid Company

Patent Attorneys for the Applicant
SPRUSON & FERGUSON

000000

0000

00

0000



TCW/79Z